▶ On-demand  |  Watch anytime🌐 On-demand Course
Laboratory investigation of analytical results and quality trends
Laboratory

OOS and OOT Investigations Masterclass - Best Practices, Key Components and FDA Requirements

This masterclass builds the capability to classify, investigate, and document OOS and OOT events with disciplined scientific reasoning, reducing exposure to inspection findings, product impact decisions, and recurring quality failures while strengthening internal control over laboratory and manufacturing investigations.

👤 Meredith L. Crabtree
▶ On-demand
⏰ Watch anytime

Course overview

This masterclass builds the capability to classify, investigate, and document OOS and OOT events with disciplined scientific reasoning, reducing exposure to inspection findings, product impact decisions, and recurring quality failures while strengthening internal control over laboratory and manufacturing investigations.

Why take this course

Out-of-specification (OOS) and out-of-trend (OOT) results signal potential breakdowns in process control, product quality, and data integrity. FDA expectations require structured, well-documented investigations that distinguish laboratory error from true manufacturing or analytical issues. Inadequate handling of these events remains a frequent source of Form 483 observations, warning letters, recalls, and consent decrees across pharmaceutical, biotech, dietary supplement, and contract manufacturing operations operating under CGMP regulations.

This course presents a detailed progression from initial result detection through classification, investigation phases, root cause analysis, interim controls, CAPA development, and final reporting. It clarifies Phase I and Phase II approaches, trending evaluation, repeat testing considerations, and documentation standards expected during inspection. Real enforcement examples are used to reinforce disciplined decision-making and strengthen internal investigation practices.

Two modules · Nine hours

Module 1: Foundations and Regulatory Framework

  • FDA definitions and guidance for OOS and OOT
  • Differences between OOS, OOT, and OOE (Out of Expectation)
  • Phase I vs Phase II Investigations
  • Laboratory investigation steps and best practices
  • Assigning preliminary causes and assessing lab error
  • Deviation and non-conformance documentation
  • Real-world OOS case studies
  • Data integrity risks in OOS handling

Module 2: Root Cause, CAPA, and Regulatory Expectations

  • Conducting effective root cause analysis
  • CAPA development and effectiveness checks
  • Linkage to batch disposition decisions
  • Statistical evaluation and OOT trending
  • Handling repeat results and retesting/averaging
  • Documentation standards for FDA inspection readiness
  • Responding to 483s and regulatory expectations for OOS/OOT

Why Strong OOS/OOT Investigations Matter

Effective handling of atypical results directly influences batch disposition, regulatory exposure, and overall quality credibility. This course strengthens decision-making around investigation triggers, retesting practices, trending evaluation, and CAPA linkage, helping organizations avoid procedural gaps that frequently surface during FDA inspections under CGMP oversight.

How This Course Structure Builds Investigation Discipline

The seminar follows the natural progression of an atypical result, beginning with regulatory definitions and laboratory assessment before advancing to root cause evaluation, corrective actions, and inspection readiness. Each stage builds on the prior discussion, reinforcing cumulative reasoning rather than isolated topics, and mirroring how investigations unfold in real operations.

Designed for your role

Quality Assurance DepartmentsQuality Control DepartmentsManufacturing DepartmentsOperations DepartmentsRegulatory Affairs DepartmentsCompliance DepartmentsValidation DepartmentsTechnical ServicesAuditing/Internal AuditorsLaboratory AnalystsCAPA CoordinatorsSite Heads and Directors of Quality

Meet the faculty

Meredith L. Crabtree
Meredith L. Crabtree

Meredith Crabtree has over 30 years’ experience in regulated industries, ranging from Blood, Plasma, Tissue, Laboratory, Pharma, Medical Device, Cosmetics, Supplements, and Animal Health. This includes manufacturing, packaging, labelling and distribution operations. Meredith is the owner of MLKC Consulting is s a Quality Consultant specializing in product label reviews, 3rd party inspections, Consent Decree and Recall support. She also performs regulatory assessments and Quality trainings.

Watch the course

▶ On-demand
⏰ Watch anytime
▶ On-demand
Register Now →

Start with an investigation review checklist.

Read our OOS/OOT escalation guide and download twelve questions for your next QA/QC discussion. No signup required.

Read the guide and get the checklist →
← Explore all webinars   ·   Registration and payments are completed on educraft.us.